Medizinische Universität Graz - Research portal
Selected Publication:
DUMMER, W; BECKER, JC; SCHWAAF, A; LEVERKUS, M; MOLL, T; BROCKER, EB.
ELEVATED SERUM LEVELS OF INTERLEUKIN-10 IN PATIENTS WITH METASTATIC MALIGNANT-MELANOMA
MELANOMA RES. 1995; 5(1): 67-68.
Doi: 10.1097/00008390-199502000-00008
Web of Science
FullText
FullText_MUG
Google Scholar
- Co-authors Med Uni Graz
- Becker Jürgen Christian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Interleukn-10 (IL-10), originally described as a product of TH2 cell clones, has been recognized as a potential immunosuppressive cytokine. To investigate the relevance of IL-10 in melanoma patients in vivo, we studied IL-10 serum levels in 104 untreated patients in different stages of the disease; 20 healthy subjects and 22 patients with inflammatory dermatoses served as controls. Serum levels were measured by ELISA. Only one of 31 patients with stage I melanoma (3%) and one of 16 stage II patients (6%) showed detectable IL-10 levels. Interestingly, six of 17 patients with lymph node metastases (stage III, 35%) and 29 of 40 patients with wide-spread disease (stage IV, 73%) revealed IL-10 levels of 15-480 pg/ml. No healthy person and only one control patient had a detectable IL-10 serum level. The data suggest that IL-10 in melanoma patients may contribute to down-modulation of anti-tumour responses in vivo.